Quaternary heterocyclylamino .BETA.-lactams. IV. Comparison of the in vivo antibacterial activities of L-640,876, mecillinam, cefoxitin and cefotaxime.

CELOZZI EVEMARIE, PELAK BARBARA ANN, STAPLEY EDWARD O., GADEBUSCH HANS H.

doi:10.7164/antibiotics.36.64

Quaternary heterocyclylamino .BETA.-lactams. IV. Comparison of the in vivo antibacterial activities of L-640,876, mecillinam, cefoxitin and cefotaxime.

DOI PubMed

CELOZZI EVEMARIE

Merck Sharp & Dohme Research Laboratories
PELAK BARBARA ANN

Merck Sharp & Dohme Research Laboratories
STAPLEY EDWARD O.

Merck Sharp & Dohme Research Laboratories
GADEBUSCH HANS H.

Merck Sharp & Dohme Research Laboratories

書誌事項

タイトル別名

IV. COMPARISON OF THE <i>IN VIVO</i> ANTIBACTERIAL ACTIVITIES OF L-640, 876, MECILLINAM, CEFOXITIN AND CEFOTAXIME

この論文をさがす

CiNii Books

説明

The novel β-lactam, L-640, 876, exhibited excellent therapeutic activity when administered parenterally but not orally to mice infected with a variety of pathogenic bacteria. In this respect, the compound was as potent as cefotaxime against representative Gram-positive and Gram-negative organisms, in most cases, equal to or more potent than cefoxitin, and more effective than mecillinam. When administered subcutaneously to normal mice at dose levels ranging from 10 to 50 mg/kg, L-640, 876 provided an adequate dose response, recovery of ca. 45% of biological activity in the urine, and excellent distribution at the highest dose level into liver, lung, kidney, heart muscle, but not brain.